1333375-02-2
1333375-02-2
Chemical Structure
BF-175
- CAS. Nr.: 1333375-02-2
- Formula:C20H21BCl2O2
- Molecular Weight:375.10
InChIKey: QQAGHMVHZOMHPO-AATRIKPKSA-N
SMILES: CC1(OB(C2=CC=C(C=C2)/C=C/C3=CC(Cl)=CC(Cl)=C3)OC1(C)C)C
Biological Activity: BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BF-175 | BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hong Q, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 2018 Jun;93(6):1330-1343. [Content Brief]
- [2]. Wang Q, et al. BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro. Mol Cell Endocrinol. 2021 Mar 1;523:111135. [Content Brief]
